Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration (PRIMAlia)

Restoration of Central Vision With the PRIMA Products in Patients With Photoreceptor Degeneration

The objective of this study is to evaluate the efficacy and safety of the PRIMA Products in participants with inherited retinal degeneration affecting the macula (including but not limited to Stargardt disease, and Retinitis Pigmentosa).

Eligible participants will be implanted with the PRIMA Stim implant. The participants will be assessed with various visual function and functional vision tests at defined timepoints throughout the clinical investigation with the PRIMA Products. The purpose of this study is to gather enough clinical data to support the clinical evaluation required for the continuous development to improve the PRIMA Products.

Study Overview

• Status: Recruiting
• Conditions: Stargardt Disease; Inherited Retinal Degeneration; Retinitis Pigmentosa (RP)
• Intervention / Treatment: Device: PRIMA Products

Detailed Description

Science has developed the PRIMA Products, which are designed to restore limited visual perception in severely sight-impaired persons with a functional optic nerve and retinal ganglion cell layers who have lost their central vision due to the degeneration of photoreceptor cells.

The PRIMA Products have been tested successfully in 38 patients with Geographic Atrophy. PRIMA was found to be both safe and effective in this population. This exploratory study is to investigate whether patients with inherited retinal degeneration affecting the macula can also benefit from PRIMA.

The objective of this study is to evaluate the efficacy and safety of the PRIMA Products in participants with inherited retinal degeneration, affecting the macula and resulting in photoreceptor degeneration, including Stargardt disease and retinitis pigmentosa. The investigation is sponsored by Science Corporation Australia.

• Study Type: Interventional
• Enrollment (Estimated): 5
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Ralf Hornig, PhD; Phone Number: +33185731835; Email: clinical-trial@science.xyz

Study Locations

• Australia
  • New South Wales
    • Sydney, New South Wales, Australia, 2006
      • Recruiting
      • Sydney Eye Hospital
      • Contact: Matthew Simunovic, Prof.; Phone Number: +61 2 9382 7111; Email: SESLHD-Mail@health.nsw.gov.au

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Is 18 years or older at the date of inclusion;
2. Has a confirmed diagnosis of inherited retinal degeneration with the macula affected in both eyes;
3. The study eye has best corrected visual acuity of logMAR 1.2 (20/320) or worse as measured by ETDRS test;
4. Has an atrophic patch in the study eye including the fovea of at least the implant size (>4.5 mm2 and >2.4 mm in minimum diameter);
5. Understands the constraints of the study and accepts to present for all scheduled follow-up visits;
6. Signed the informed consent.

Exclusion Criteria:

1. 1. Has cataract in the study eye (with LOCS III scale NO, NC, C or P>1); (these patients will need to have cataract surgery performed prior to completion of baseline testing; all other patients will get IOL replacement during the PRIMA Stim implantation);
2. Underwent intraocular lens implantation in the study eye within the last month prior to enrolment (this corresponds to 4 weeks or 28 days) ;
3. Has an implanted IOL in the study eye and a refraction of the study eye outside of -4D; +4D limit (this criterion is not relevant for phakic eyes)
4. Has a highly myopic study eye (>26 mm AP);
5. Has no light perception in either eye;
6. Has a history of documented choroidal neovascularization in either eye;
7. Has any signs of exudative AMD including exudative AMD with detachment of retinal pigment epithelium in the central visual field of the study eye;
8. Has an implanted telescope in one eye;
9. Has a black IOL in the study eye;
10. Has any disease (other than study allowed diseases) or condition that affects retinal function of the study eye or the visual system (e.g., central retinal artery/vein occlusion, end-stage diabetic retinopathy, Proliferative Diabetic Retinopathy (PDR), diabetic macular oedema (DME), severe Non-Proliferative Diabetic Retinopathy (NPDR), retinal detachment, infectious or inflammatory retinal disease, severe glaucoma, optic neuropathy, etc.) ;
11. Has any disease or condition that prevents adequate examination (including Optical Coherence Tomography (OCT)) of the study eye including but not limited to media opacities that cannot be resolved prior to implantation. Note, that this criterion is also important for the function of the implant;
12. Has a corneal endothelial cell count of less than 1000 cells/mm² in the study eye;
13. Suffers from nystagmus or other ocular motility disorders;
14. Has any disease or condition that precludes the understanding or communication of the informed consent, study requirements or test protocols (e.g., deafness, severe multiple sclerosis, amyotrophic lateral sclerosis, severe neuritis, etc.);
15. Has uncontrolled epileptic seizures;
16. Has a known sensitivity to the contact materials of the implant (iridium oxide, silicon-carbide and titanium);
17. Has a known allergy to anaesthetic drugs;
18. Presents with hypotonia in the study eye (<8 mmHg);
19. Presents with hypertonia in the study eye (>23 mmHg with treatment);
20. Has active cancer or a history of intraocular, optic nerve or brain cancer and metastasis;
21. Is an immune-suppressed participant (e.g., due to HIV positive diagnosis, etc.);
22. Is a known carrier of multi-resistant microorganisms;
23. Is receiving anticoagulation therapy that cannot be adapted to allow eye surgery;
24. Is participating in another investigational drug or device study that may interfere with the PRIMAlia study;
25. Has a history of chronic or recurrent infection or inflammation that would preclude participation in the study;

26. Has significant recurrent or chronic inflammations or infections. Specifically, patients with the following disorders are excluded:

    • Severe chronic and consuming diseases that frequently associated with infection (e.g. Crohn disease, Whipple's disease);
    • Active inflammation in the area of the eye (e.g. herpes of cornea and/or conjunctiva, recurrent blepharoconjunctivitis, hordeolum, chalazion);
27. Has a severe psychological disorder;
28. Does not have the mental capacity to legally sign the informed consent;
29. Has severe renal, cardiac, hepatic, etc. organ diseases (ASA IV or worse);
30. Has head dimensions that are incompatible with the PRIMA Companion glasses;
31. Has too high and/or unrealistic expectations (e.g., believes that a benefit is guaranteed or expects normal vision after surgery).
32. Physical constraints making use of PRIMA or rehabilitation impossible
33. Participant who, in the opinion of the investigator, is not suitable for participation in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PRIMA Products	Device: PRIMA Products; Implantation of PRIMA, Vision training, follow up

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of participants with an improvement of visual acuity	Proportion of participants with an improvement of visual acuity of logMAR 0.2 or more	12 months
Number and severity of device and procedure related serious adverse events	Number and severity of device and procedure related serious adverse events	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of participants with an improvement of visual acuity	Proportion of participants with an improvement of visual acuity of logMAR 0.2 or more	6, 24 and 36 months
Mean improvement in visual acuity	Mean improvement in visual acuity measured by ETDRS (extended by the Berkeley Rudimentary Vision Test)	6, 12, 24 and 36 months
Number and severity of procedure and device related adverse events throughout the study	Number and severity of procedure and device related adverse events throughout the study	up to 36 months
Change of natural visual acuity	Change of natural visual acuity from baseline without the PRIMA Companion glasses measured by ETDRS (extended by the Berkeley Rudimentary Vision Test)	up to 36 months
Mean improvement in the reading test	Mean improvement in reading acuity, measured using the Radner Reading Charts and reported on the logRAD (Reading Acuity Determination) scale. The logRAD scale ranges from 1.2 logRAD (worst reading acuity) to -0.2 logRAD (best reading acuity) at 40 cm. Lower logRAD values indicate better reading acuity.	12, 24 and 36 months

Collaborators and Investigators

• Sponsor: Science Corporation

Publications and helpful links

Helpful Links

• Science Corporation

Study record dates

Study Major Dates

• Study Start (Estimated): March 12, 2026
• Primary Completion (Estimated): March 1, 2029
• Study Completion (Estimated): March 1, 2031

Study Registration Dates

• First Submitted: November 19, 2025
• First Submitted That Met QC Criteria: November 24, 2025
• First Posted (Actual): December 5, 2025

Study Record Updates

• Last Update Posted (Actual): April 2, 2026
• Last Update Submitted That Met QC Criteria: March 27, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Genetic Diseases, Inborn; Eye Diseases; Eye Diseases, Hereditary; Retinal Diseases; Retinal Dystrophies; Retinal Degeneration; Macular Degeneration; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Stargardt Disease; Retinitis Pigmentosa
• Other Study ID Numbers: CIP-PRIMA-AUS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No